EPA:SAN - Sanofi Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
€66.17 -0.06 (-0.09 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close€66.23
Today's Range€65.87 - €66.58
52-Week Range€63.09 - €92.97
Volume6.89 million shs
Average Volume3.05 million shs
Market Capitalization$82.98 billion
P/E RatioN/A
Dividend Yield4.58%
BetaN/A

About Sanofi (EPA:SAN)

Sanofi logoSanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Receive SAN News and Ratings via Email

Sign-up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolEPA:SAN
CUSIPN/A
Phone+33-1-53774000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-0.27%
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares1,260,000,000

Sanofi (EPA:SAN) Frequently Asked Questions

What is Sanofi's stock symbol?

Sanofi trades on the EPA under the ticker symbol "SAN."

What price target have analysts set for SAN?

16 analysts have issued twelve-month target prices for Sanofi's stock. Their predictions range from €60.00 to €94.00. On average, they expect Sanofi's share price to reach €77.63 in the next twelve months. View Analyst Ratings for Sanofi.

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:
  • Mr. Olivier Brandicourt, CEO & Director (Age 62)
  • Mr. Jérôme Contamine, CFO & Exec. VP (Age 61)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Mr. George Grofik, Head of Investor Relations

Has Sanofi been receiving favorable news coverage?

News headlines about SAN stock have trended somewhat positive on Friday, according to Accern. Accern scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sanofi earned a media sentiment score of 0.18 on Accern's scale. They also assigned news coverage about the company an impact score of 47.20 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

What is Sanofi's stock price today?

One share of SAN stock can currently be purchased for approximately €66.17.

How big of a company is Sanofi?

Sanofi has a market capitalization of $82.98 billion.

How can I contact Sanofi?

Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000.


MarketBeat Community Rating for Sanofi (SAN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  427 (Vote Outperform)
Underperform Votes:  521 (Vote Underperform)
Total Votes:  948
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sanofi (EPA:SAN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
16 Wall Street analysts have issued ratings and price targets for Sanofi in the last 12 months. Their average twelve-month price target is €77.63The high price target for SAN is €94.00 and the low price target for SAN is €60.00. There are currently 2 sell ratings, 10 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.132.132.252.25
Ratings Breakdown: 2 Sell Rating(s)
10 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
10 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: €77.63€79.50€83.00€87.81

Sanofi (EPA:SAN) Consensus Price Target History

Price Target History for Sanofi (EPA:SAN)

Sanofi (EPA:SAN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/10/2018JPMorgan Chase & Co.Set Price TargetNeutral€72.00View Rating Details
5/8/2018Goldman Sachs GroupSet Price TargetNeutral€74.00View Rating Details
4/30/2018CfraSet Price TargetNeutral€68.00View Rating Details
4/30/2018Credit Suisse GroupSet Price TargetBuy€80.00View Rating Details
4/30/2018Deutsche BankSet Price TargetBuy€88.00View Rating Details
4/30/2018BarclaysSet Price TargetSell€60.00View Rating Details
4/13/2018Jefferies GroupSet Price TargetNeutral€72.00View Rating Details
4/9/2018Berenberg BankSet Price TargetNeutral€83.00View Rating Details
3/28/2018Morgan StanleySet Price TargetSell€66.00View Rating Details
3/12/2018Kepler Capital MarketsSet Price TargetBuy€84.00View Rating Details
3/2/2018UBSSet Price TargetNeutral€68.00View Rating Details
2/8/2018Societe GeneraleSet Price TargetBuy€94.00View Rating Details
2/7/2018Sanford C. BernsteinSet Price TargetNeutral€82.00View Rating Details
1/23/2018S&P GlobalSet Price TargetNeutral€78.00View Rating Details
10/6/2017CitigroupSet Price TargetNeutral€88.00View Rating Details
9/12/2017BNP ParibasSet Price TargetNeutral€85.00View Rating Details
6/30/2016Independent ResearchSet Price TargetNeutral€77.00View Rating Details
6/9/2016Baader BankSet Price TargetNeutral€78.00View Rating Details
(Data available from 5/25/2016 forward)

Earnings

Dividends

Sanofi (EPA:SAN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sanofi (EPA SAN) Insider Trading and Institutional Ownership History

Insider Trading History for Sanofi (EPA:SAN)

Sanofi (EPA SAN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Sanofi (EPA SAN) News Headlines

Source:
DateHeadline
NOTICE IN RELATION TO THE CONVERTIBLE BONDS DUE MAY 2020NOTICE IN RELATION TO THE CONVERTIBLE BONDS DUE MAY 2020
globenewswire.com - May 25 at 5:30 PM
Form 6-K Sanofi For: May 22Form 6-K Sanofi For: May 22
www.streetinsider.com - May 22 at 4:58 PM
Lexicon Pharma: FDA To Review Sanofis Filing For Zynquista - Quick FactsLexicon Pharma: FDA To Review Sanofi's Filing For Zynquista - Quick Facts
www.nasdaq.com - May 22 at 4:58 PM
BRIEF-Sanofi Says FDA To Review Zynquista As Potential Treatment For Type 1 DiabetesBRIEF-Sanofi Says FDA To Review Zynquista As Potential Treatment For Type 1 Diabetes
www.reuters.com - May 22 at 4:58 PM
Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab ...Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab ...
globenewswire.com - May 21 at 5:00 PM
Sanofi (SNY) option implied volatility into ASCOSanofi (SNY) option implied volatility into ASCO
www.streetinsider.com - May 17 at 5:57 PM
Sanofi: Accelerating Future Breakthroughs Through Clinical Trials -- Part 2 of 3Sanofi: Accelerating Future Breakthroughs Through Clinical Trials -- Part 2 of 3
www.prnewswire.com - May 17 at 5:57 PM
Regeneron (REGN), Sanofi (SNY) Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung ...Regeneron (REGN), Sanofi (SNY) Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung ...
www.streetinsider.com - May 16 at 5:19 PM
Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ...Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ...
www.prnewswire.com - May 16 at 5:19 PM
Trump Administration Rolls Out Shaming as Drug Pricing ToolTrump Administration Rolls Out Shaming as Drug Pricing Tool
finance.yahoo.com - May 16 at 5:19 PM
Is Sanofi’s (NYSE:SNY) Balance Sheet Strong Enough To Weather A Storm?Is Sanofi’s (NYSE:SNY) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - May 14 at 5:09 PM
JPMorgan Chase Analysts Give Sanofi (SAN) a €72.00 Price TargetJPMorgan Chase Analysts Give Sanofi (SAN) a €72.00 Price Target
www.americanbankingnews.com - May 10 at 2:19 PM
Sanofi Genzyme to lay off 95 workers at Framingham manufacturing siteSanofi Genzyme to lay off 95 workers at Framingham manufacturing site
www.bizjournals.com - May 9 at 5:17 PM
France says Iran deal "not dead", Macron to contact RouhaniFrance says Iran deal "not dead", Macron to contact Rouhani
finance.yahoo.com - May 9 at 8:38 AM
Sanofi (SAN) Given a €74.00 Price Target at Goldman SachsSanofi (SAN) Given a €74.00 Price Target at Goldman Sachs
www.americanbankingnews.com - May 8 at 10:22 AM
Global Pediatric Vaccines Market Competitive landscape: Merck & Co Inc, Pfizer Inc, Sanofi SAGlobal Pediatric Vaccines Market Competitive landscape: Merck & Co Inc, Pfizer Inc, Sanofi SA
www.marketwatch.com - May 7 at 5:23 PM
Sanofi SA (SAN) Receives Average Rating of "Hold" from BrokeragesSanofi SA (SAN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 6 at 10:19 AM
Form 6-K Sanofi For: May 03Form 6-K Sanofi For: May 03
www.streetinsider.com - May 3 at 5:10 PM
Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates ViewRegeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View
finance.yahoo.com - May 3 at 5:10 PM
Sanofi Named to DiversityIncs Top 50 Companies for Diversity®Sanofi Named to DiversityInc's Top 50 Companies for Diversity®
www.prnewswire.com - May 2 at 5:21 PM
Sanofi (SAN) Given a €80.00 Price Target at Credit Suisse GroupSanofi (SAN) Given a €80.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - April 30 at 12:22 PM
Cfra Reiterates €68.00 Price Target for Sanofi (SAN)Cfra Reiterates €68.00 Price Target for Sanofi (SAN)
www.americanbankingnews.com - April 30 at 12:21 PM
Sanofi (SAN) Given a €74.00 Price Target by Goldman Sachs AnalystsSanofi (SAN) Given a €74.00 Price Target by Goldman Sachs Analysts
www.americanbankingnews.com - April 30 at 10:36 AM
Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell CarcinomaSanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
finance.yahoo.com - April 30 at 8:40 AM
Sanofi (SAN) PT Set at €88.00 by Deutsche BankSanofi (SAN) PT Set at €88.00 by Deutsche Bank
www.americanbankingnews.com - April 30 at 8:22 AM
Sanofi (SAN) PT Set at €60.00 by BarclaysSanofi (SAN) PT Set at €60.00 by Barclays
www.americanbankingnews.com - April 30 at 6:42 AM
Edited Transcript of SAN.PA earnings conference call or presentation 27-Apr-18 12:30pm GMTEdited Transcript of SAN.PA earnings conference call or presentation 27-Apr-18 12:30pm GMT
finance.yahoo.com - April 28 at 8:51 AM
Sanofi Q1 top line flat; pharma sales down 1%; Lantus sales down 18%; shares down 2% premarketSanofi Q1 top line flat; pharma sales down 1%; Lantus sales down 18%; shares down 2% premarket
seekingalpha.com - April 27 at 5:04 PM
Sanofi (SNY) Reports Q1 EPS of EUR1.28 (Earlier)Sanofi (SNY) Reports Q1 EPS of EUR1.28 (Earlier)
www.streetinsider.com - April 27 at 5:04 PM
Sanofis (SNY) CEO Olivier Brandicourt on Q1 2018 Results - Earnings Call TranscriptSanofi's (SNY) CEO Olivier Brandicourt on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 27 at 5:04 PM
Sanofi (SNY) Reports FDA Review Accepted for Supplemental Biologics License Application for 0.5 mL Dose of ...Sanofi (SNY) Reports FDA Review Accepted for Supplemental Biologics License Application for 0.5 mL Dose of ...
www.streetinsider.com - April 25 at 5:17 PM
BRIEF-FDA Accepts For Review Sanofis Supplemental Biologics License ApplicationBRIEF-FDA Accepts For Review Sanofi's Supplemental Biologics License Application
www.reuters.com - April 25 at 5:17 PM
Too Many Drugmakers Chase Same Targets, Sanofis Zerhouni SaysToo Many Drugmakers Chase Same Targets, Sanofi's Zerhouni Says
www.bloomberg.com - April 25 at 5:17 PM
FDA accepts for review Supplemental Biologics License Application for 0.5 mL dose of Fluzone® Quadrivalent (Influenza Vaccine) in children 6-35 months of ageFDA accepts for review Supplemental Biologics License Application for 0.5 mL dose of Fluzone® Quadrivalent (Influenza Vaccine) in children 6-35 months of age
finance.yahoo.com - April 25 at 5:17 PM
Sanofi Names Roches John Reed Head Of Global R&D, Succeeding Elias ZerhouniSanofi Names Roche's John Reed Head Of Global R&D, Succeeding Elias Zerhouni
www.nasdaq.com - April 24 at 5:23 PM
Form 6-K Sanofi For: Apr 24Form 6-K Sanofi For: Apr 24
www.streetinsider.com - April 24 at 5:23 PM
Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1
finance.yahoo.com - April 24 at 8:35 AM
UK bans Sanofi epilepsy drug without pregnancy prevention planUK bans Sanofi epilepsy drug without pregnancy prevention plan
finance.yahoo.com - April 24 at 8:35 AM
Sanofi (EPA:SAN): Immense Growth Potential?Sanofi (EPA:SAN): Immense Growth Potential?
finance.yahoo.com - April 24 at 8:35 AM
UBS Reiterates €82.00 Price Target for Sanofi (SAN)UBS Reiterates €82.00 Price Target for Sanofi (SAN)
www.americanbankingnews.com - April 20 at 9:46 PM
Berkeley Lights Announces New Agreement With Sanofi for Beacon® OptoFluidic PlatformBerkeley Lights' Announces New Agreement With Sanofi for Beacon® OptoFluidic Platform
www.prnewswire.com - April 19 at 5:22 PM
WHO recommends testing before use of Sanofis dengue vaccineWHO recommends testing before use of Sanofi's dengue vaccine
finance.yahoo.com - April 19 at 5:22 PM
Form 6-K Sanofi For: Apr 18Form 6-K Sanofi For: Apr 18
www.streetinsider.com - April 18 at 5:30 PM
Sanofi Finance Chief to Leave After Almost a Decade at DrugmakerSanofi Finance Chief to Leave After Almost a Decade at Drugmaker
www.bloomberg.com - April 18 at 5:30 PM
Advent in exclusive talks to buy Sanofi generics businessAdvent in exclusive talks to buy Sanofi generics business
www.ft.com - April 17 at 5:41 PM
Sanofis CFO Contamine to retire later this yearSanofi's CFO Contamine to retire later this year
finance.yahoo.com - April 17 at 5:41 PM
[$$] Charterhouse Portfolio Company Closes Sanofi Deal[$$] Charterhouse Portfolio Company Closes Sanofi Deal
finance.yahoo.com - April 16 at 5:07 PM
Sanofis (SAN) "Neutral" Rating Reiterated at JPMorgan ChaseSanofi's (SAN) "Neutral" Rating Reiterated at JPMorgan Chase
www.americanbankingnews.com - April 15 at 11:42 PM
Sanofi (SAN) PT Set at €89.00 by Kepler Capital MarketsSanofi (SAN) PT Set at €89.00 by Kepler Capital Markets
www.americanbankingnews.com - April 15 at 8:54 PM
Advent nears deal to buy Sanofi generics businessAdvent nears deal to buy Sanofi generics business
www.ft.com - April 15 at 6:24 PM

SEC Filings

Sanofi (EPA:SAN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Sanofi (EPA SAN) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.